Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($11.12) per share for the quarter.
Sonnet BioTherapeutics Price Performance
NASDAQ SONN opened at $1.62 on Wednesday. The company has a fifty day simple moving average of $1.78 and a 200 day simple moving average of $2.22. Sonnet BioTherapeutics has a 12-month low of $1.41 and a 12-month high of $18.72.
Wall Street Analyst Weigh In
Separately, Chardan Capital reduced their price objective on shares of Sonnet BioTherapeutics from $30.00 to $20.00 and set a “buy” rating for the company in a report on Friday, December 20th.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Stories
- Five stocks we like better than Sonnet BioTherapeutics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Stock Dividend Cuts Happen Are You Ready?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
